EuropeHealth

Pancreatic Cancer: EU Approves New Treatment

The European Commission has approved a new medicine for adults with advanced pancreatic cancer. The treatment, called daraxonrasib, could help patients live longer.

The approval came on Tuesday, November 17, 2026. It offers a new treatment option for patients who have already received cancer treatment.

US biotechnology company Revolution Medicines developed the medicine. Patients take it as a tablet.

New Treatment Shows Promising Results

An international clinical study compared daraxonrasib with chemotherapy.

The results showed a difference in average survival:

  •  Patients who received daraxonrasib lived for an average of 12.4 months.
  •  Patients who received chemotherapy alone lived for an average of 6.7 months.

These results suggest that the new medicine may help extend the lives of some patients with advanced pancreatic cancer.

However, daraxonrasib does not cure the disease. Doctors must assess each patient’s condition before recommending a treatment.

EMA Completed a Faster Review

The European Medicines Agency (EMA) reviewed the medicine through an accelerated procedure.

The agency completed its scientific assessment in just over 100 days. This is much faster than the standard review period of 210 days.

The European Commission granted approval because patients with this form of cancer have limited treatment options.

Daraxonrasib had also received approval in the United States earlier in 2026.

What Does This Mean for Patients in Europe?

The EU approval marks an important development in the treatment of advanced pancreatic cancer.

However, approval does not automatically mean that every patient can access the medicine immediately. Availability, pricing and reimbursement arrangements may differ between European countries.

Patients should speak with their cancer specialists about available treatments and whether daraxonrasib may be suitable for them.

The new medicine does not offer a cure. However, the study results provide hope for patients who need more treatment options.

This article provides general health information and does not replace advice from a qualified medical professional.

Enjoyed this story? Add Belgium Brief as a preferred source on Google to see more of our Belgium news.

Add as preferred source

Back to top button